NASDAQ:QURE - Uniqure Stock Price, Price Target & More

$29.80 +1.02 (+3.54 %)

(As of 04/25/2018 04:00 PM ET)

Previous Close$28.78

Today's Range$28.60 - $30.79

52-Week Range$4.72 - $32.71

Volume222,763 shs

Average Volume373,431 shs

Market Capitalization$987.15 million

P/E Ratio-10.14

Dividend YieldN/A

Beta0.18

About Uniqure (NASDAQ:QURE)

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics, and Chiesi Farmaceutici S.p.A. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Receive QURE News and Ratings via Email

Sign-up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:QURE

CUSIPN/A

Webwww.uniqure.com

Phone31-20-566-7394

Debt

Debt-to-Equity Ratio0.22%

Current Ratio8.46%

Quick Ratio8.46%

Price-To-Earnings

Trailing P/E Ratio-10.14

Forward P/E Ratio-9.28

P/E GrowthN/A

Sales & Book Value

Annual Sales$13.11 million

Price / Sales72.22

Cash FlowN/A

Price / CashN/A

Book Value$2.90 per share

Price / Book10.28

Profitability

EPS (Most Recent Fiscal Year)($2.94)

Net Income$-79,260,000.00

Net Margins-604.72%

Return on Equity-174.25%

Return on Assets-46.88%

Miscellaneous

Employees202

Outstanding Shares31,770,000

How to Become a New Pot Stock Millionaire

Uniqure (NASDAQ:QURE) Frequently Asked Questions

What is Uniqure's stock symbol?

Uniqure trades on the NASDAQ under the ticker symbol "QURE."

How were Uniqure's earnings last quarter?

Uniqure NV (NASDAQ:QURE) posted its quarterly earnings data on Wednesday, March, 14th. The biotechnology company reported ($0.91) EPS for the quarter, missing the Zacks' consensus estimate of ($0.68) by $0.23. The biotechnology company had revenue of $2.58 million for the quarter, compared to the consensus estimate of $2.83 million. Uniqure had a negative net margin of 604.72% and a negative return on equity of 174.25%. View Uniqure's Earnings History.

When is Uniqure's next earnings date?

Uniqure is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Uniqure.

What price target have analysts set for QURE?

7 brokerages have issued twelve-month price objectives for Uniqure's shares. Their forecasts range from $13.00 to $35.00. On average, they anticipate Uniqure's share price to reach $23.8333 in the next twelve months. View Analyst Ratings for Uniqure.

Are investors shorting Uniqure?

Uniqure saw a drop in short interest in April. As of April 13th, there was short interest totalling 751,751 shares, a drop of 29.8% from the March 30th total of 1,070,529 shares. Based on an average trading volume of 322,800 shares, the days-to-cover ratio is currently 2.3 days. Currently, 3.9% of the company's shares are short sold.

Who are some of Uniqure's key competitors?

Some companies that are related to Uniqure include FibroGen (FGEN), GW Pharmaceuticals (GWPH), Advanced Accelerator Application (AAAP), Ligand Pharmaceuticals (LGND), Blueprint Medicines (BPMC), Array BioPharma (ARRY), Tesaro (TSRO), Emergent BioSolutions (EBS), Ultragenyx Pharmaceutical (RARE), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), Evotec A.G. (EVTCY), Ascendis Pharma (ASND), Clovis Oncology (CLVS) and Acadia Pharmaceuticals (ACAD).

Who are Uniqure's key executives?

Uniqure's management team includes the folowing people:

Mr. Matthew Craig Kapusta, CEO, Interim CFO & Exec. Director (Age 46)
Dr. Sander Van Deventer, Co-Founder, Chief Scientific Officer, Director, Advisor & GM of Amsterdam (Age 64)
Prof. Hugo Katus, Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
Dr. Scott T. McMillan Ph.D., Chief Operating Officer (Age 59)
Mr. Christian Klemt, Chief Accounting Officer (Age 45)

Has Uniqure been receiving favorable news coverage?

Press coverage about QURE stock has been trending somewhat positive recently, according to Accern. Accern scores the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Uniqure earned a media sentiment score of 0.18 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 46.03 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Uniqure?

Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Uniqure's stock price today?

One share of QURE stock can currently be purchased for approximately $29.80.

How big of a company is Uniqure?

Uniqure has a market capitalization of $987.15 million and generates $13.11 million in revenue each year. The biotechnology company earns $-79,260,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis. Uniqure employs 202 workers across the globe.

How can I contact Uniqure?

Uniqure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at 31-20-566-7394 or via email at [email protected]

MarketBeat Community Rating for Uniqure (QURE)

Community Ranking:		3.4 out of 5 ( )
Outperform Votes:		386 (Vote Outperform)
Underperform Votes:		186 (Vote Underperform)
Total Votes:		572

MarketBeat's community ratings are surveys of what our community members think about Uniqure and other stocks. Vote "Outperform" if you believe QURE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QURE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Uniqure (NASDAQ:QURE) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

7 Wall Street analysts have issued ratings and price targets for Uniqure in the last 12 months. Their average twelve-month price target is $23.8333, suggesting that the stock has a possible downside of 20.02%. The high price target for QURE is $35.00 and the low price target for QURE is $13.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.86	2.75	2.75	2.71
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$23.8333	$21.5714	$19.8571	$14.40
Price Target Upside:	20.02% downside	2.38% upside	0.19% upside	5.01% downside

Uniqure (NASDAQ:QURE) Consensus Price Target History

Price Target History for Uniqure (NASDAQ:QURE)

Uniqure (NASDAQ:QURE) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/23/2018	HC Wainwright	Set Price Target	Buy	$35.00	High
3/20/2018	Janney Montgomery Scott	Reiterated Rating	Buy	$30.00	High
11/24/2017	Oppenheimer	Reiterated Rating	Hold		Low
11/7/2017	Leerink Swann	Boost Price Target		$19.00 -> $26.00	N/A
11/7/2017	Evercore ISI	Initiated Coverage	Outperform -> Outperform	$22.00	N/A
7/23/2017	Chardan Capital	Set Price Target	Buy	$13.00	High
5/24/2017	Cowen	Reiterated Rating	Buy		Medium
4/12/2017	Jefferies Group	Reiterated Rating	Hold	$8.00	Low
12/6/2016	WallachBeth Capital	Lower Price Target	Buy	$27.00 -> $15.00	N/A
11/15/2016	Piper Jaffray	Downgrade	Overweight -> Neutral		N/A

(Data available from 4/25/2016 forward)

Uniqure (NASDAQ:QURE) Earnings History and Estimates Chart

Earnings by Quarter for Uniqure (NASDAQ:QURE)

Uniqure (NASDAQ:QURE) Earnings Estimates

2018 EPS Consensus Estimate: ($2.90)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.81)	($0.81)	($0.81)
Q2 2018	1	($0.80)	($0.80)	($0.80)
Q3 2018	1	($0.81)	($0.81)	($0.81)
Q4 2018	1	($0.48)	($0.48)	($0.48)

Uniqure (NASDAQ QURE) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/8/2018
3/14/2018	Q4 2017	($0.68)	($0.91)	$2.83 million	$2.58 million	View	N/A
11/1/2017	Q3 2017	($0.65)	($0.40)	$7.60 million	$2.26 million	View	N/A
8/8/2017	6/30/2017	($0.78)	($0.83)	$2.92 million	$4.94 million	View	N/A
5/9/2017	3/31/2017	($0.64)	($0.80)	$4.20 million	$3.32 million	View	N/A
3/15/2017	Q4 2016	($0.52)	($0.58)	$6.60 million	$9.13 million	View	N/A
11/22/2016	Q3 2016	($0.86)	($0.60)	$4.10 million	$7.21 million	View	N/A
8/25/2016	Q2 2016	($0.87)	($0.98)	$4.08 million	$1.82 million	View	N/A
5/31/2016	Q1	($0.8220)	($0.9250)	$2.94 million	$4.30 million	View	N/A
4/4/2016	Q415	($0.60)	($0.58)	$2.78 million	$6.78 million	View	N/A
11/30/2015	Q315	($0.64)	($1.1410)	$7.76 million	$3.50 million	View	Listen
8/27/2015	Q215	($0.56)	($0.9820)	$31.18 million	$1.79 million	View	N/A
6/11/2015	Q1	($0.8160)	($0.69)	$9.50 million	$1.17 million	View	N/A
4/6/2015		($0.62)	($0.77)	$1.38 million	$1.61 million	View	N/A
12/1/2014		($0.53)	($0.61)	$2.00 million	$1.30 million	View	N/A
9/2/2014	Q214	($0.55)	($1.35)	$1.40 million	$1.37 million	View	N/A
6/6/2014		($0.45)	($0.52)	$0.84 million	$1.59 million	View	N/A

(Earnings results data provided by Zacks Investment Research)

Uniqure (NASDAQ:QURE) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Uniqure (NASDAQ QURE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.73%
Institutional Ownership Percentage: 42.77%

Insider Trading History for Uniqure (NASDAQ:QURE)

Uniqure (NASDAQ QURE) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/15/2018	Matthew C Kapusta	CEO	Sell	39,169	$21.72	$850,750.68	439,764
1/29/2018	David Schaffer	Director	Sell	2,878	$18.53	$53,329.34	15,314
1/29/2018	Deventer Sander Van	Insider	Sell	5,985	$18.53	$110,902.05
1/4/2018	Matthew C. Kapusta	CEO	Sell	21,690	$19.87	$430,980.30
1/3/2018	Christian Klemt	Insider	Sell	5,093	$20.13	$102,522.09
1/3/2018	Maria E. Cantor	SVP	Sell	5,864	$20.13	$118,042.32
6/29/2017	Harald Petry	Insider	Sell	49,300	$6.02	$296,786.00	27,753
6/27/2017	Harald Petry	Insider	Sell	65,930	$6.01	$396,239.30	155
6/26/2017	Harald Petry	Insider	Sell	58,075	$6.01	$349,030.75	155
6/22/2017	Harald Petry	Insider	Sell	155	$6.00	$930.00	155

(Data available from 1/1/2013 forward)

Uniqure (NASDAQ QURE) News Headlines

Source:

Date	Headline
	uniQure Delivers Oral Presentation on Broad Set of Preclinic www.lse.co.uk - April 25 at 5:09 PM
	uniQure Delivers Oral Presentation on Broad Set of Preclinical Data on AMT-130 in Huntington's Disease at the 2018 ... globenewswire.com - April 25 at 5:09 PM
	uniQure Delivers Oral Presentation on Broad Set of Preclinical Data on AMT-130 in Huntington’s Disease at the 2018 American Academy of Neurology Annual Meeting finance.yahoo.com - April 25 at 5:09 PM
	Uniqure (QURE) Given a $35.00 Price Target at HC Wainwright www.americanbankingnews.com - April 23 at 9:48 AM
	Opinion: Harry Boxer's biotech-stock breakouts to watch www.marketwatch.com - April 20 at 8:55 AM
	Uniqure (QURE) Rating Increased to Hold at ValuEngine www.americanbankingnews.com - April 16 at 7:35 PM
	Analyst Ratings for UniQure and Its Peers in April 2018 finance.yahoo.com - April 13 at 5:06 PM
	An In-Depth Look at UniQure’s Cash Flows and Valuation finance.yahoo.com - April 13 at 5:06 PM
	Insights into UniQure’s Financial Performance finance.yahoo.com - April 13 at 5:06 PM
	UniQure’s Promising Research Pipeline finance.yahoo.com - April 13 at 5:06 PM
	Uniqure (QURE) Lifted to Buy at BidaskClub www.americanbankingnews.com - April 13 at 10:45 AM
	How Do Analysts See uniQure NV. (NASDAQ:QURE) Performing In The Next Couple Of Years? finance.yahoo.com - April 13 at 9:00 AM
	Zacks: Brokerages Expect Uniqure NV (QURE) Will Announce Quarterly Sales of $3.08 Million www.americanbankingnews.com - April 13 at 2:35 AM
	Zacks Investment Research Upgrades Uniqure (QURE) to Hold www.americanbankingnews.com - April 12 at 12:33 PM
	Opinion: Harry Boxer's five biotech stocks to watch www.marketwatch.com - April 11 at 5:03 PM
	Zacks: Analysts Expect Uniqure NV (QURE) to Announce -$0.74 Earnings Per Share www.americanbankingnews.com - April 11 at 3:10 PM
	Uniqure Sees Unusually High Options Volume (QURE) www.americanbankingnews.com - April 10 at 8:03 AM
	Novartis Wager on AveXis Shows Rare Diseases Command Mega Prices www.bloomberg.com - April 9 at 4:57 PM
	Novartis CEO Spurs Rare-Disease Shift With $8.7 Billion Deal www.bloomberg.com - April 9 at 8:59 AM
	Zacks Investment Research Upgrades Uniqure (QURE) to "Hold" www.americanbankingnews.com - April 7 at 7:02 AM
	After $1 Million Drug Flop, UniQure Seeks Gene-Therapy Revival www.bloomberg.com - April 6 at 9:00 AM
	Uniqure (QURE) Stock Rating Upgraded by Zacks Investment Research www.americanbankingnews.com - April 5 at 11:19 PM
	Uniqure (QURE) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - April 4 at 9:30 AM
	ValuEngine Upgrades Uniqure (QURE) to Buy www.americanbankingnews.com - April 3 at 10:07 AM
	Uniqure NV (QURE) Given Consensus Recommendation of "Buy" by Analysts www.americanbankingnews.com - April 1 at 3:30 PM
	Evercore ISI Begins Coverage on Uniqure (QURE) www.americanbankingnews.com - April 1 at 3:10 PM
	Uniqure (QURE) Downgraded to "Sell" at Zacks Investment Research www.americanbankingnews.com - March 29 at 5:16 PM
	Uniqure (QURE) Downgraded to "Hold" at BidaskClub www.americanbankingnews.com - March 28 at 12:00 AM
	$3.08 Million in Sales Expected for Uniqure NV (QURE) This Quarter www.americanbankingnews.com - March 27 at 3:58 AM
	Uniqure (QURE) Upgraded to "Buy" at BidaskClub www.americanbankingnews.com - March 24 at 6:46 PM
	Janney: Buy The Dip In Uniqure - Benzinga www.benzinga.com - March 21 at 9:41 AM
	Janney: Buy The Dip In Uniqure finance.yahoo.com - March 20 at 4:52 PM
	Uniqure (QURE) Given Buy Rating at Janney Montgomery Scott www.americanbankingnews.com - March 20 at 12:35 PM
	Insider Selling: Uniqure NV (QURE) CEO Sells 39,169 Shares of Stock www.americanbankingnews.com - March 19 at 4:14 PM
	Report: Developing Opportunities within Itau Unibanco Banco Holding SA, NantHealth, Southern First Bancshares, uniQure N.V., Ascendis Pharma A/S, and National General — Future Expectations, Projections Moving into 2018 finance.yahoo.com - March 16 at 8:55 AM
	Uniqure (QURE) Stock Rating Reaffirmed by HC Wainwright www.americanbankingnews.com - March 15 at 2:11 PM
	BRIEF-UniQure ‍on Track To Begin Pivotal Study Of AMT-061 In Hemophilia B In Q3 www.reuters.com - March 14 at 6:30 PM
	uniQure Announces 2017 Financial Results and Recent Company Progress - Nasdaq www.nasdaq.com - March 14 at 9:23 AM
	Form 8-K uniQure NV For: Mar 14 - StreetInsider.com www.streetinsider.com - March 14 at 9:23 AM
	uniQure reports FY results - Seeking Alpha seekingalpha.com - March 14 at 9:23 AM
	uniQure Announces 2017 Financial Results and Recent Company Progress finance.yahoo.com - March 14 at 9:23 AM
	Uniqure NV (QURE) Expected to Announce Quarterly Sales of $2.83 Million www.americanbankingnews.com - March 10 at 8:40 AM
	Uniqure NV (QURE) Given Consensus Rating of "Buy" by Analysts www.americanbankingnews.com - March 7 at 3:45 PM
	Royce & Associates LP Takes Position in Uniqure NV (QURE) www.americanbankingnews.com - March 6 at 10:53 AM
	Prosight Management LP Purchases New Position in Uniqure NV (QURE) www.americanbankingnews.com - March 5 at 4:38 PM
	181,378 Shares in Uniqure NV (QURE) Purchased by Bogle Investment Management L P DE www.americanbankingnews.com - March 4 at 4:54 AM
	Uniqure NV (QURE) Short Interest Update www.americanbankingnews.com - March 3 at 1:54 AM
	uniQure to Participate in Multiple Conferences in March - GlobeNewswire (press release) globenewswire.com - February 27 at 8:50 AM
	uniQure to Participate in Multiple Conferences in March finance.yahoo.com - February 27 at 8:50 AM
	66,270 Shares in Uniqure NV (QURE) Purchased by Victory Capital Management Inc. www.americanbankingnews.com - February 25 at 5:52 AM

Uniqure (NASDAQ:QURE) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Uniqure (NASDAQ:QURE) Income Statement, Balance Sheet and Cash Flow Statement

Uniqure (NASDAQ QURE) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff